<DOC>
	<DOC>NCT00969150</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.</brief_summary>
	<brief_title>Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Men and women, 1880 years old Currently meet the DSMIVTR criteria for Major Depressive Disorder The patient's current depressive episode must be at least 4 weeks in duration Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control Patients with a history of meeting DSMIVTR criteria for: any manic or hypomanic episode schizophrenia or any other psychotic disorder obsessivecompulsive disorder Patients who are considered a suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>